UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employer Identification No.) (State or other jurisdiction ...

O ato Selecta.. Biosciences Corporate Presentation April 2 0 2 0 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate sup ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) | Delawar | | --- | Delaware 26-1622110 (I.R.S. Employer ...

Selecta Biosciences, Inc. (SELB) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET Company Participants Elona Kogan - General Counsel Carsten Brunn - President and Chief Executive Officer Brad Dahms - Chief Financial Officer Kei Kishimoto - Chief Scientific Officer Conference Call Participants Ellie Merle - Cantor Fitzgerald Raju Prasad - William Blair Chad Messer - Needham & Company John Newman - Canaccord Yun Zhong - Janney Difei Yang - Mizuho Securities USA Operator Good morning and welcome to ...

O ရှိ Selecta.. Biosciences Corporate Presentation February 2020 Nasdaq SELB Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate sup ...

O श्रे Selecta… Biosciences Corporate Presentation January 2020 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate supe ...

O ato Selecta… Biosciences Corporate Presentation November 2019 SELB Nasdaq Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate supe ...

Selecta Biosciences, Inc. (SELB) Q3 2019 Results Earnings Conference Call November 8, 2019 8:30 AM ET Company Participants Elona Kogan - Corporate Secretary, General Counsel Carsten Brunn - President, Chief Executive Officer Alison Schecter - Chief Medical Officer Brad Dahms - Chief Financial Officer Conference Call Participants Chad Messer - Needham & Company Bill Grau - Stifel Chris French - Canaccord Alex Lim - Mizuho Yun Zhong - Janney Operator Good morning and welcome to the Selecta Biosciences' third ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37798 Selecta Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 26-1622110 (I.R.S. Employer Identification No.) (State or other jurisdic ...

O ato Selecta. Biosciences Corporate Presentation October 2019 Nasdaq SELB Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ("the company"), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate super ...